trimebutine
General
Canada-Approved Medicine
This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.
Pronunciation:
try-meh-boo-teen
Trade Name(s)
- Modulon
Ther. Class.
lower gastrointestinal tract motility regulators
spasmolytics
Indications
- Symptomatic treatment of irritable bowel syndrome (IBS).
- Treatment of postoperative paralytic ileus.
Action
Acts as a spasmolytic.
Therapeutic Effect(s):
- ↓ symptoms of IBS.
- Resumption of intestinal transit following abdominal surgical procedures.
Pharmacokinetics
Absorption: Rapidly absorbed following oral administration.
Distribution: Unknown.
Metabolism and Excretion: Extensively metabolized, <2.4% excreted unchanged in urine.
Half-life: 2.7–3.1 hr.
TIME/ACTION PROFILE (symptom relief)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | within 3 days–2 wk | 1 hr (blood level) | >1 wk (following discontinuation) |
Contraindication/Precautions
Contraindicated in:
- Hypersensitivity.
Use Cautiously in:
- OB: Not recommended for use;
- Pedi: Children <12 yr (safety and effectiveness not established).
Adverse Reactions/Side Effects
CNS: dizziness, drowsiness, fatigue, headache
GI: diarrhea, dry mouth, dysguesia, dyspepsia, epigastric pain, nausea
Derm: hot/cold sensation, rash
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Interactions
Drug-Drug
None known
Route/Dosage
PO (Adults): 200 mg 3 times daily.
Availability
Tablets: 100 mg, 200 mg
Assessment
- Assess for symptoms of irritable bowel syndrome (cramping, constipation and diarrhea, mucus in stools).
- Assess for abdominal distention and assess bowel sounds.
- Monitor intake and output and record.
Potential Diagnoses
- Acute pain
- Diarrhea
Implementation
- PO Administer three times daily before meals.
Patient/Family Teaching
- Instruct patient to take trimebutine as directed.
- Advise female patient to inform health care professional if pregnancy is planned or suspected or if breast feeding.
Evaluation/Desired Outcomes
Decrease signs and symptoms of irritable bowel disease.
To view other topics, please log in or purchase a subscription.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Complete Product Information.